Japan Recommends First PCSK9 Inhibitor
This article was originally published in PharmAsia News
Executive Summary
Japan has issued a positive approval recommendation for the first PCSK9-targeting biologic in the country, Amgen Astellas BioPharma's Repatha, which now looks set to reach the market early next year.